Cyclo Therapeutics Inc CYTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTH is a good fit for your portfolio.
News
-
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
-
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
-
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
-
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.27–1.31
- 52-Week Range
- $0.68–2.57
- Bid/Ask
- $1.29 / $1.31
- Market Cap
- $37.04 Mil
- Volume/Avg
- 16,463 / 99,168
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
Valuation
|
Metric
|
CYTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.80 |
Price/Sales | 19.72 |
Price/Cash Flow | — |
Price/Earnings
CYTH
Financial Strength
|
Metric
|
CYTH
|
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.45 |
Interest Coverage | — |
Quick Ratio
CYTH
Profitability
|
Metric
|
CYTH
|
|---|---|
Return on Assets (Normalized) | −303.78% |
Return on Equity (Normalized) | −3,840.77% |
Return on Invested Capital (Normalized) | −2,613.39% |
Return on Assets
CYTH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Wcfkfgsjh | Fxztsc | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Qypshfzmt | Bsqdf | $68.9 Bil | |
HLN
| Haleon PLC ADR | Hlpbtqp | Hvr | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Hlzzknmgp | Nptxh | $14.7 Bil | |
VTRS
| Viatris Inc | Gxfyykcy | Jwcx | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qgtgjggl | Zpjm | $11.9 Bil | |
CTLT
| Catalent Inc | Zskwzxj | Mjggqpz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Bptbyfml | Wqnlh | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Qqrthvlbb | Lql | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vjvlfkn | Dcjbc | $3.5 Bil |